Table 3 Comparison of cases with false-negative BRAF results and other cases
Variable | Group 1 (n = 36) | Group 2 (n = 185) | P value |
|---|---|---|---|
(FN group) | (TP + FP + TN group) |  | |
Gender (F/M) | 33/3 (91.7%) | 146/39 (78.9%) | 0.121 |
Age | 51.7 ± 9.5 | 45.6 ± 12.8 | 0.002 |
Tumor size | 0.78 ± 0.72 | 0.93 ± 0.70 | 0.241 |
Extrathyroidal extension | 17 (47.2%) | 56 (30.3%) | 0.074 |
Lymph node metastasis | 20 (55.6%) | 92 (49.7%) | 0.647 |
Bethesda system |  |  | < 0.001 |
 Nondiagnostic | 10 (27.8%) | 6 (3.2%) |  |
 Benign | 0 | 0 |  |
 AUS | 4 (11.1%) | 7 (3.8%) |  |
 (Suspicious) FN | 0 | 0 |  |
 Suspicious | 11 (30.6%) | 28 (15.1%) |  |
 Malignant | 11 (30.6%) | 144 (77.8%) |  |
Subtype of PTC | Â | Â | 0.036 |
 Conventional | 30 (83.3%) | 131 (70.8%) |  |
 Follicular variant | 4 (11.1%) | 43 (23.2%) |  |
 Clear cell variant | 0 | 3 (1.6%) |  |
 Oncocytic variant | 0 | 7 (3.8%) |  |
 Tall cell variant | 2 (5.6%) | 1 (0.5%) |  |